ArticleBMC cancer2026
Early-life infections and childhood cancer risk: a nationwide cohort study of 2 million children.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe relationship between early-life infections and childhood cancer risk remains unclear despite its importance for risk stratification and clinical surveillance.
methodsWe conducted a nationwide population-based cohort study using the South Korean National Health Information Database. Children born between January 1, 2002, and December 31, 2006, were followed through December 31, 2019. Two analytic cohorts were defined: Cohort 1 (n = 1,996,174) evaluated the number of infection episodes during ages 0–4 years, with a restricted analysis of infections occurring between ages 2–4 years; Cohort 2 (n = 1,999,065) evaluated infections during ages 0–1 year. Infection episodes were defined using healthcare visits with relevant ICD-10 diagnostic codes. Incident childhood cancer was ascertained from claims records. Multivariable Cox models estimated hazard ratios (HRs) adjusting for sex, residence, income quintile, and birth year.
resultsHazard ratios (HRs) were estimated relative to the lowest infection frequency category for each infectious disease. Upper respiratory tract infections, pneumonia, and influenza were not associated with increased cancer risk. At ages 0–1 year, risk increased with 2–4 lower respiratory infections (HR 1.06, 95% CI 1.00–1.12), ≥ 2 enteric infections (HR 1.11, 95% CI 1.01–1.22), ≥ 1 urinary infection (HR 1.21, 95% CI 1.09–1.33), and ≥ 2 mycoses (HR 1.19, 95% CI 1.03–1.38). At ages 2–4 years, risk remained elevated for ≥ 1 urinary infection (HR 1.13, 95% CI 1.02–1.25) and for skin infections (HR 1.09, 95% CI 1.02–1.17 for one episode; HR 1.13, 95% CI 1.03–1.24 for ≥ 2 episodes). Hospitalization showed a dose–response pattern: for ages 0–4 years, HRs were 1.07 (95% CI 1.00–1.14) for one admission, 1.17 (95% CI 1.04–1.32) for two, and 1.30 (95% CI 1.14–1.47) for ≥ 3; for ages 0–1 year, 1.07 (95% CI 1.00–1.15) for one and 1.22 (95% CI 1.05–1.41) for ≥ 2; for ages 2–4 years, 1.12 (95% CI 1.04–1.21) for one and 1.18 (95% CI 1.03–1.36) for ≥ 2. Limitations include potential outcome and exposure misclassification inherent to claims data, unmeasured confounding (e.g., genetic susceptibility, environmental factors), and use of hospitalization as a proxy for infection severity.
conclusionsInfections managed in outpatient settings were not associated with increased cancer risk, whereas infections requiring hospitalization—used as a proxy for more severe infections—were associated with higher cancer incidence and showed a dose–response pattern. Infection severity and frequency may be relevant to childhood cancer development and risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.